How Does Retatrutide Make You Feel?

Retatrutide is an investigational triple receptor agonist developed by Eli Lilly, currently without a marketing authorisation in the UK or elsewhere. Understanding how retatrutide makes you feel requires looking at what clinical trial participants have reported, including changes in appetite, gastrointestinal symptoms and energy levels, alongside the side effects and safety signals recorded in published and ongoing trials. This article summarises findings from authorised research, explains the regulatory context, and outlines what is and is not yet known about the subjective and physical effects of this unlicensed investigational medicine.

What is retatrutide and what is its regulatory status in the UK?

Retatrutide holds no marketing authorisation in the UK and is available only to participants in authorised clinical trials; it cannot be prescribed, supplied or obtained through a GP, pharmacy or online clinic.

Retatrutide holds no marketing authorisation in the UK or anywhere else, meaning it is not a licensed medicine and cannot be advertised, and can be prescribed or supplied only within an authorised clinical trial.^[1] It is an investigational drug developed by Eli Lilly that acts on three hormone receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple agonist mechanism distinguishes it pharmacologically from currently authorised medicines such as tirzepatide (Mounjaro), which targets two receptors, and semaglutide (Wegovy, Ozempic), which targets one.^[6][7]

Because retatrutide is investigational, it is available only to participants enrolled in authorised clinical trials under strict research protocols. It cannot be obtained through a GP, a pharmacy or an online clinic, and no UK launch date has been announced. Anyone encountering a product sold online under this name should be aware that it cannot be a licensed medicine and may be a falsified or counterfeit product, which carries serious safety risks. If you are interested in licensed weight-management treatments, your GP can discuss options that are currently authorised and available.

What did clinical trial participants report feeling on retatrutide?

Phase 2 trial participants reported reduced hunger, earlier fullness and diminished interest in food, consistent with GLP-1 receptor agonist effects; some also noted changes in energy levels in the early weeks of treatment.

Clinical trial participants in the Phase 2 retatrutide study, published in the New England Journal of Medicine in 2023, reported a range of subjective experiences broadly consistent with the known effects of GLP-1 receptor agonist medicines.^[2][3] The most commonly described sensations related to appetite and food intake: participants reported reduced hunger, earlier feelings of fullness during meals, and a diminished interest in food overall. These effects are understood to arise from the drug's action on GLP-1 receptors in the gut and brain, which slow gastric emptying and influence satiety signalling.^[8][9]

Some participants also reported changes in energy levels, particularly in the early weeks of treatment. These changes may reflect the body adapting to reduced caloric intake; the contribution of glucagon receptor agonism to energy expenditure in humans is a hypothesis supported by preclinical and mechanistic data but has not yet been confirmed in published human trials of retatrutide specifically, and should be understood as a proposed rather than established explanation.^[10]

It is important to note that these reported experiences come from a controlled trial setting, with participants who were closely monitored and who met specific eligibility criteria. Trial participants were excluded if they were pregnant, breastfeeding or planning pregnancy, and contraception requirements applied throughout. Phase 3 trials, including the TRIUMPH and TRANSCEND programmes, are providing further data across broader populations and longer durations; some results from these programmes have been presented at scientific congresses, though not all have been published in full peer-reviewed form at the time of writing.^[11] The subjective experience of any individual outside a trial cannot be predicted from these findings.

What side effects and physical symptoms have been recorded in trials?

The most frequently recorded side effects were gastrointestinal, including nausea, vomiting, diarrhoea and constipation, particularly during dose escalation, with injection-site reactions and appetite-related fatigue also reported.

The most frequently recorded side effects in retatrutide trials have been gastrointestinal in nature, which is consistent with the class of GLP-1 receptor agonist medicines. In the Phase 2 trial reported in the New England Journal of Medicine, nausea, vomiting, diarrhoea and constipation were among the most commonly reported adverse events, particularly during dose escalation periods.^[2][3] These symptoms were generally described as mild to moderate in severity and tended to decrease over time as participants adjusted to the treatment. Preliminary data from the TRANSCEND and TRIUMPH Phase 3 programmes, presented at scientific congresses, suggest a broadly similar gastrointestinal profile, though full peer-reviewed publications are awaited for some trials.

Persistent vomiting or an inability to keep fluids down warrants prompt contact with the trial team, as dehydration is a practical risk with prolonged gastrointestinal symptoms. Trial participants should follow the reporting instructions given to them at enrolment.

Physical symptoms such as injection-site reactions, including redness, itching or mild discomfort at the site of administration, were also noted, as is typical with subcutaneous injectable medicines. Some participants reported decreased appetite to a degree that affected their overall food and fluid intake, which can contribute to feelings of fatigue or light-headedness, particularly in the early weeks.

Gallbladder and biliary events are a recognised signal across the GLP-1 receptor agonist class and have been observed in trials of related medicines; whether retatrutide carries a similar risk is not yet fully characterised from published data, and this will be an area to monitor as Phase 3 results are reported in full.^[12][13]

The glucagon receptor agonism component of retatrutide may also influence blood glucose levels, and in participants with type 2 diabetes, hypoglycaemia (low blood sugar) is a potential concern, especially when used alongside other glucose-lowering medicines. Symptoms of hypoglycaemia can include shakiness, sweating, confusion and palpitations.^[18]

Because retatrutide remains investigational, the full side-effect profile continues to be characterised as Phase 3 trial data are published. The data available to date should be understood as preliminary, and the safety picture may evolve as larger and more diverse populations are studied over longer periods.

Are there any serious risks or safety concerns to be aware of?

Serious risks include acute pancreatitis, hypoglycaemia in people with type 2 diabetes, and transient worsening of diabetic retinopathy; trial participants must report adverse events to their trial team and carry their study identification card at all times.

Several serious safety signals have been identified in retatrutide trials and warrant careful consideration. Acute pancreatitis has been reported in association with GLP-1 receptor agonist medicines as a class, and as retatrutide shares this mechanism, the risk cannot be excluded.^[14][12] Symptoms that may indicate pancreatitis include severe and persistent abdominal pain, sometimes radiating to the back, accompanied by nausea or vomiting. Anyone experiencing such symptoms should seek urgent medical attention by calling 999 or attending an accident and emergency department.

Rapid improvements in blood glucose control, which may occur with potent glucose-lowering agents, can be associated with transient worsening of pre-existing diabetic eye disease, particularly in people who already have pre-proliferative or proliferative diabetic retinopathy.^[15][16] This is a recognised phenomenon across the GLP-1 class and is not unique to retatrutide, but it underlines the importance of thorough ophthalmological assessment in people with existing diabetic eye conditions before and during any intensive glucose-lowering treatment.

Because retatrutide is available only within authorised clinical trials, any adverse events experienced by trial participants must be reported to the trial team in accordance with the study protocol. Trial participants should carry their study identification card at all times and inform any emergency clinician that they are enrolled in a clinical trial and receiving an investigational medicine, so that appropriate care decisions can be made. Suspected side effects may also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Retatrutide is not authorised for use outside a clinical trial, and no safety monitoring infrastructure exists for unsupervised use. Products sold online claiming to be retatrutide are not licensed medicines and may contain unknown or harmful substances. If you have concerns about your health or are considering weight-management treatment, contact your GP in the first instance.

Frequently Asked Questions